RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.9988 (−66.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RedHill Biopharma Ltd. saw revenue fall 96.4% to $286.00K over fiscal 2025. Free cash flow was -$9.66M.
Revenue
$286.00K
-96.4% vs. a year earlier
Operating income
-$7.94M
FY2025
Free cash flow
-$9.66M
FY2025
EPS, diluted
$0.00
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $286.00K
- EPS, diluted
- $0.00
- Free cash flow
- -$9.66M
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
$286.00K-96.4% YoY
Gross profit
–
Operating income
-$7.94M
EPS, diluted
$0.00
Free cash flow
-$9.66M
Reported period